Diagnostic workup of patients with congenital adrenal hyperplasia; Part of metyrapone testing in the workup of suspected secondary or tertiary adrenal insufficiency; Part of metyrapone testing in the differential diagnostic workup of Cushing syndrome.
The 14-3-3? protein appears to contribute to the pathologic process of joint erosion and, as such, is an emerging biomarker of joint damage in rheumatoid arthritis (RA) and psoriatic arthritis. Concentrations are significantly higher in people with active joint disease than in those with inactive RA or psoriasis without arthritis. Measurement of 14-3-3? complements RF and CCP antibody tests and may improve diagnostic sensitivity.
Ancillary test for congenital adrenal hyperplasia (CAH), particularly in situations in which a diagnosis of 21-hydroxylase and 11-hydroxylase deficiency have been ruled out; for confirming a diagnosis of 3-b-hydroxydehydrogenase (3-b-HSD) deficiency and 17-alphahydroxylase deficiency; and as part of a battery of tests to evaluate females with hirsutism or infertility, both of which can result from adult-onset CAH.
This test detects copy number changes of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) using fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded tissue specimens. FISH is performed using two separate hybridizations, each with two FISH probes. One hybridization employs a probe specific to 1p36 along with a control 1q25 probe. The other employs a probe specific to 19q13 with a control 19p13 probe. The presence or absence of a deletion is determined by the signal ratio of each respective probe pair. 1p/19q co-deletion occurs in 44-69% of classic oligodendrogliomas and 21-33% of mixed oligoastrocytomas. This alteration is relatively infrequent in pure astrocytomas (6-8%) and can therefore be useful in the classification of gliomas. In addition, 1p/19q co-deletion is associated with more favorable prognosis and response to specific chemotherapeutic and radiotherapeutic regimens - particularly in anaplastic oligodendroglioma or oligoastrocytoma.